FibroGen Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Okay. Good afternoon, one. I'm Paul Choi, the SMid cap biotechnology analyst at Goldman Sachs. We'll continue with our next session here, which is FibroGen. And I'm very pleased to introduce from management, Enrique Conterno, who's, I think, a well-known quantity to investors. He's the CEO here at FibroGen.
I think as with other sessions, what we'll do is let Enrique do a few brief introductory remarks and give us an overview of what he's finding to be going on at FibroGen. And then we'll proceed with the Q&A. (Operator Instructions) And with that, Enrique, I'll turn it over to you for some opening comments.
Very good, Paul. Thank you very much for the invitation. It's a pleasure to be here.
I'm very excited with the agenda that we have at FibroGen. As I've mentioned in the past, we are very committed to 3 overarching goals. #1 is to ensure that regulatory and commercial success of roxadustat, and we are
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |